Olympus (7733.T): Shares fall about 13% after FDA warning letter on six facilities

Olympus, the Japanese maker of endoscopes (thin camera instruments used to look inside the body), said on 13 October that the US Food and Drug Administration (FDA) sent it a warning letter about its quality systems at six facilities. Its Tokyo-listed shares fell roughly 13% to 14% the next day, while the company says production, sales and new product clearances are not restricted.

What happened

On 13 October 2026, Olympus announced that it had received a Warning Letter from the FDA, dated 7 October (US time). A warning letter is a formal notice that the regulator believes a company has not fixed problems it found during inspections. This one follows FDA inspections of Olympus sites in the US, Japan and Europe in late 2025, and it concerns the quality management system (the written processes for building and checking products), specifically whether Olympus's answers to the inspectors' written observations (known as Form 483s) were adequate. The six sites are Olympus Medical Systems at Hachioji and Hinode, Aomori Olympus and Shirakawa Olympus in Japan, Olympus Winter & IBE in Hamburg, Germany, and Gyrus ACMI in Brooklyn Park, Minnesota.

Olympus says it will send a full response within 15 business days of receiving the letter and then give regular updates until the FDA judges its actions adequate. It states that the letter does not restrict its ability to make, market or distribute products, does not require a recall, and does not stop it applying for FDA 510(k) clearance, the route for approving many new devices. On 14 October the shares fell about 13.5% in Tokyo to roughly ¥1,759, according to MarketScreener, with the fall reported as the biggest in about 15 years. GuruFocus put the close at 13.2% lower and the intraday low at 16.7% lower, so we describe the move as roughly 13% to 14% at the close.

The numbers, explained

The letter itself carries no figures, so the best guide to what is at stake is Olympus's most recent results, for the three months to 30 June 2026, published on 7 August. Revenue was ¥240,400 million (about ¥240.4 billion) against ¥206,512 million a year earlier: ¥33,888 million more, or 16.4%. Adjusted operating profit, the profit from running the business before some one-off items, was ¥30,676 million against ¥13,188 million, up 132.6% (our working: 17,488 divided by 13,188 is 1.326). As a share of sales that is 12.8% against 6.4%, so Olympus kept about 12.8 yen of every 100 yen of sales as adjusted operating profit, up from about 6.4.

Two other numbers matter for context. First, Olympus said earlier voluntary shipping pauses and FDA import alerts (orders that can stop products entering the US) cut revenue by about ¥13 billion in the quarter, mainly in its surgical and interventional business; our working puts that at about 5.4% of the ¥240.4 billion reported (13 divided by 240.4). That figure comes from Olympus's results release only, and it relates to existing issues rather than this new letter. Second, the business is uneven: the gastrointestinal division, which sells endoscopes, had revenue of ¥168,448 million, up 21.2%, and operating profit of ¥38,646 million, while the surgical and interventional division had revenue of ¥71,923 million, up 6.7%, and an operating loss of ¥2,404 million. For the full year to March 2027 Olympus's own forecast is revenue of ¥1,055 billion to ¥1,076 billion and adjusted operating profit of ¥160.5 billion to ¥179.5 billion; the first quarter's ¥30.7 billion is 17.1% to 19.1% of that range.

Why it matters

Olympus makes much of its money from endoscopes, the tools used with them, and servicing contracts, sold to healthcare providers; its gastrointestinal division alone brought in ¥168.4 billion of the ¥240.4 billion quarterly revenue. Regulators and hospitals depend on a manufacturer's quality system to show that devices are made and repaired consistently, so a warning letter signals that the FDA does not yet consider the fixes sufficient. Olympus says it has been putting corrective and preventive actions in place since the inspections ended in late 2025, and its results release says the FDA has not yet classified last autumn's inspections. For customers, the company says its products remain safe and effective when used as instructed.

The size of the share fall is notable because Olympus said it does not expect the letter to affect its consolidated financial results, and the sources we read do not explain the gap. One possible reason, and this is our commentary, is history: Olympus has already carried shipping pauses and import alerts. GuruFocus quotes unnamed analysts who say systemic quality problems could take more than several quarters to resolve, which is opinion rather than fact. We report the market reaction as fact and the reasons as unconfirmed.

What to watch next

Olympus has said it will respond to the FDA within 15 business days of receiving the letter, so that response is the next dated step. It has also said it will provide periodic updates until the FDA is satisfied, and the results release notes that the FDA has not yet issued a classification for the inspections held last autumn. The company reaffirmed its full-year forecast in August, with the ship-hold impact expected to ease in the second half of its financial year, which ends on 31 March 2027. We make no prediction about the outcome.

Sources

• Olympus: Olympus Receives FDA Warning Letter (13 Oct 2026)
• Olympus: Reports First Quarter Fiscal 2027 Financial Results
• Olympus: Consolidated Financial Results for the Three Months Ending 30 June 2026 (filing)
• MarketScreener: Olympus Corporation Receives Warning Letter From FDA
• GuruFocus: Olympus (OCPNY) Faces Major Stock Drop Following FDA Warning
• Investing.com: Why is Olympus stock plunging today?